Skip to main content
Top
Published in: Familial Cancer 4/2018

01-10-2018 | Original Article

Urological sequelae of desmoids associated with familial adenomatous polyposis

Authors: S. J. Walton, G. Malietzis, S. K. Clark, E. Havranek

Published in: Familial Cancer | Issue 4/2018

Login to get access

Abstract

The aim of this retrospective cohort study was to review urological complication rates arising from familial adenomatous polyposis associated desmoid tumours and their management. All patients over a 35-year period were identified from a prospectively maintained polyposis registry database and had an intra-abdominal desmoid tumour. Those without ureteric complications (n = 118, group A) were compared to those that developed ureteric obstruction (n = 40, group B) for demographics, treatment interventions and survival outcomes. 158 (56% female) patients were identified. Median age at diagnosis was 31 years and desmoids typically occurred 3.6 years after colectomy for familial adenomatous polyposis. Ureteric obstruction secondary to tumour growth occurred in 25% of cases. There was no significant difference in gender distribution or overall age at desmoid diagnosis between the two groups. In group B, the median age at desmoid diagnosis was significantly younger in women compared to men (25 and 43 years, respectively) (p = 0.01). Thirty-eight percent of patients already had ureteric obstruction at desmoid diagnosis, the remainder occurred after 48.6 months, but 20 years in two cases. Seventy-three percent (29/40) had ureteric stenting, a long-term requirement for most. Permanent renal injury occurred in six cases but survival between the two groups was not significantly different. Ureteric obstruction occurs frequently in patients with familial adenomatous polyposis and an intra-abdominal desmoid tumour. Those most at risk are the young following colectomy. Clinicians should actively survey the renal tract at regular intervals after a diagnosis of an intra-abdominal desmoid tumour as complications can arise insidiously, at any stage.
Literature
1.
go back to reference Reitamo JJ, Hayry P, Nykyri E, Saxen E (1982). The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673CrossRef Reitamo JJ, Hayry P, Nykyri E, Saxen E (1982). The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673CrossRef
2.
go back to reference Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Böker T, Augustin A, Kadmon M, Möslein G, Thomas G et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4:337–340CrossRef Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Böker T, Augustin A, Kadmon M, Möslein G, Thomas G et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4:337–340CrossRef
3.
go back to reference Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y (1998) Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 10:591–594PubMed Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y (1998) Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 10:591–594PubMed
4.
go back to reference Huss S, Nehles J, Binot E, Wardelmann E, Mittler J, Kleine MA et al (2013) Beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology 62:294–304CrossRef Huss S, Nehles J, Binot E, Wardelmann E, Mittler J, Kleine MA et al (2013) Beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology 62:294–304CrossRef
5.
go back to reference Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100:1658–1664CrossRef Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100:1658–1664CrossRef
6.
go back to reference Sturt NJ, Clark SK (2006). Current ideas in desmoid tumours. Fam Cancer 5:275–285 (discussion 87–8)CrossRef Sturt NJ, Clark SK (2006). Current ideas in desmoid tumours. Fam Cancer 5:275–285 (discussion 87–8)CrossRef
7.
go back to reference Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713CrossRef Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704–713CrossRef
8.
go back to reference Nieuwenhuis MH, Lefevre JH, Bulow S, Järvinen H, Bertario L, Kernéis S, Parc Y, Vasen HF et al (2011) Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 54:1229–1234CrossRef Nieuwenhuis MH, Lefevre JH, Bulow S, Järvinen H, Bertario L, Kernéis S, Parc Y, Vasen HF et al (2011) Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 54:1229–1234CrossRef
9.
go back to reference Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13:1222–1229CrossRef Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK (2011) Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 13:1222–1229CrossRef
10.
go back to reference Schlemmer M (2005) Desmoid tumors and deep fibromatoses. Hematol Oncol Clin North America 19:565–571CrossRef Schlemmer M (2005) Desmoid tumors and deep fibromatoses. Hematol Oncol Clin North America 19:565–571CrossRef
11.
go back to reference Joyce M, Mignanelli E, Church J (2010) Ureteric obstruction in familial adenomatous polyposis-associated desmoid disease. Dis Colon Rectum 53:327–332CrossRef Joyce M, Mignanelli E, Church J (2010) Ureteric obstruction in familial adenomatous polyposis-associated desmoid disease. Dis Colon Rectum 53:327–332CrossRef
12.
go back to reference Church J, Xhaja X, LaGuardia L, O’Malley M, Burke C, Kalady M (2015) Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 58:444–448CrossRef Church J, Xhaja X, LaGuardia L, O’Malley M, Burke C, Kalady M (2015) Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum 58:444–448CrossRef
Metadata
Title
Urological sequelae of desmoids associated with familial adenomatous polyposis
Authors
S. J. Walton
G. Malietzis
S. K. Clark
E. Havranek
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0064-0

Other articles of this Issue 4/2018

Familial Cancer 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine